Restricted Stock Unit Agreement under the Galectin Therapeutics Inc.Restricted Stock Unit Agreement • March 29th, 2024 • Galectin Therapeutics Inc • Pharmaceutical preparations
Pursuant to the terms of the Galectin Therapeutics Inc. 2019 Omnibus Equity Compensation Plan (the “Plan”), Galectin Therapeutics Inc., a Nevada corporation (together with all successors thereto, the “Company”), hereby enters into this Restricted Stock Unit Agreement with the undersigned employee (the “Grantee”), pursuant to which the Company will issue the number of shares of the Company’s common stock equal to the number of Restricted Stock Units (“RSU’s”) granted hereunder in accordance with the terms set forth in this agreement (the “Agreement”).
GALECTIN THERAPEUTICS INC. STOCK OPTION AGREEMENT FORStock Option Agreement • March 29th, 2024 • Galectin Therapeutics Inc • Pharmaceutical preparations
SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENTSupplemental Line of Credit Agreement • March 29th, 2024 • Galectin Therapeutics Inc • Pharmaceutical preparations
September 22, 2023Amendment and Restatement of Common Stock Purchase Warrants • March 29th, 2024 • Galectin Therapeutics Inc • Pharmaceutical preparations • Florida
This letter agreement (this “Letter Agreement”) confirms the agreement between Galectin Therapeutics, Inc. (the “Company”) and 10X Fund L.P. and 10X Capital Management LLC (collectively referred to as “10X”) regarding certain amendments with respect to an aggregate of 5,732,253 Common Stock Purchase Warrants (the “Series B Warrants”) held by 10X, which are listed on Schedule A.
